Nivolumab

You have access
Association Between Administration Timing and Efficacy of Nivolumab in Non-small Cell Lung Cancer Treatment
YUKI IWAHASHI, AKIHIRO TAMIYA, TSUNEHIRO TANAKA, MOTOHIRO TAMIYA, AKIHIRO TSUKAGUCHI, YUJI INAGAKI, YOSHIHIKO TANIGUCHI and KYOICHI OKISHIO

Anticancer Research November 2025, 45 (11) 5077-5084; DOI: https://doi.org/10.21873/anticanres.17848
You have access
Prognostic Value of the C-Reactive Protein-albumin-lymphocyte Index For Patients With Recurrent οr Metastatic Head and Neck Squamous Cell Carcinoma Treated With Nivolumab
FUMIHIKO SATO, TAKEHARU ONO, AKIRA HIRAKI, TSUNEHIRO OKA, TOSHIYUKI MITSUHASHI, MASAYASU NAITO, MIOKO FUKAHORI, SHINTARO SUEYOSHI, ITARU MIZOBE, MASAHIRO SEKI, KIMINOBU SATO, TOSHIHIKO KAWAGUCHI, HISAICHIRO TANAKA, TAKASHI KURITA, SHUN-ICHI CHITOSE and HIROHITO UMENO

Anticancer Research September 2025, 45 (9) 3993-4004; DOI: https://doi.org/10.21873/anticanres.17757
You have access
Rash and Endocrine Disorders Predict Improved Survival in Metastatic Renal Cell Carcinoma Treated With Immunotherapy
KOICHI SUGIMOTO, TAKAFUMI MINAMI, SHINGO TOYODA, LAN INOKI, TAKUHISA NUKAYA, KIYOSHI TAKAHARA, TAKAHIRO ADACHI, TAKESHI HASHIMOTO, RYOICHI MAENOSONO, TAKUYA TSUJINO, WATARU FUKUOKAYA, TAKAFUMI YANAGISAWA, TAKEHIRO IWATA, KENSUKE BEKKU, MOTOO ARAKI, TAKAHIRO KIMURA, HARUHITO AZUMA, YOSHIO OHNO, RYOICHI SHIROKI, KAZUTOSHI FUJITA and ; on behalf of the JK-FOOT STUDY GROUP

Anticancer Research August 2025, 45 (8) 3355-3364; DOI: https://doi.org/10.21873/anticanres.17696
You have access
Correlation Between Body Mass Index and Clinical Outcomes in Advanced Renal Cell Carcinoma Patients
KENSUKE BEKKU, SHOTA INOUE, KASUMI YOSHINAGA, YOSUKE MITSUI, TOMOAKI YAMANOI, TATSUSHI KAWADA, YUSUKE TOMINAGA, TAKUYA SADAHIRA, SATOSHI KATAYAMA, TAKEHIRO IWATA, SHINGO NISHIMURA, KOHEI EDAMURA, TOMOKO KOBAYASHI and MOTOO ARAKI

Anticancer Research June 2025, 45 (6) 2643-2651; DOI: https://doi.org/10.21873/anticanres.17635
You have access
Impact of Nivolumab Plus Chemotherapy on Conversion Therapy in Clinical Stage IVB HER2-negative Gastric Cancer
YUDAI HOJO, TOSHIHIKO TOMITA, MASATAKA IGETA, MOTOKI MURAKAMI, SHUGO KOHNO, EIICHIRO NAKAO, YOSHITAKA KITAYAMA, TATSURO NAKAMURA, YASUNORI KURAHASHI, YOSHINORI ISHIDA, SEIICHI HIROTA, SHINICHIRO SHINZAKI and HISASHI SHINOHARA

Anticancer Research May 2025, 45 (5) 2091-2102; DOI: https://doi.org/10.21873/anticanres.17583
Open Access
Nivolumab Plus 5-Fluorouracil/Leucovorin+Oxaliplatin for Gastric Cancer With Severe Peritoneal Metastasis
KYOKO FURUSAWA, MITSUHIRO FURUTA, MISA ONISHI, TAKANORI HAMA, SHUNTARO ISHIKAWA, KEI HAYASHI, HIROSHI NAKANOMA, KAZUO SHIOTSUKI, KOHEI TAKIZAWA, NOZOMU MACHIDA, JUNJI FURUSE and SHIN MAEDA

Anticancer Research April 2025, 45 (4) 1583-1592; DOI: https://doi.org/10.21873/anticanres.17539
You have access
Real-world Outcomes in Recurrent/Metastatic Squamous Cell Carcinoma of Head and Neck With Nivolumab: Galician Study
LETICIA IGLESIAS, ROCÍO VÍLCHEZ, SANTIAGO AGUÍN, RAMÓN GARCÍA, CAROLINA PENA, ALBERTO CARRAL, GERARDO HUIDOBRO, AUREA MOLINA, JESÚS GARCÍA GÓMEZ, MARTA COVELA, MARINHA COSTA and ANA MEDINA

Anticancer Research March 2025, 45 (3) 1181-1191; DOI: https://doi.org/10.21873/anticanres.17505
Open Access
Efficacy of Second-line Nivolumab Versus Tyrosine Kinase Inhibitors for Renal Cell Carcinoma With Bone Metastases
GAKU YAMAMICHI, TAIGO KATO, AKIHIRO YOSHIMURA, MASARU TANI, YUKI HORIBE, YUTONG LIU, NESRINE SASSI, YOHEI OKUDA, TOSHIKI OKA, TOSHIHIRO UEMURA, AKINARU YAMAMOTO, YU ISHIZUYA, TAKUJI HAYASHI, YOSHIYUKI YAMAMOTO, KOJI HATANO, ATSUNARI KAWASHIMA, TETSUYA TAKAO, KENSAKU NISHIMURA, SHINGO TAKADA, MASAO TSUJIHATA and NORIO NONOMURA

Anticancer Research February 2025, 45 (2) 639-650; DOI: https://doi.org/10.21873/anticanres.17451
You have access
Effect of Nivolumab on the Quality of Life in Recurrent/Metastatic Head and Neck Cancer
SHOTA FUJII, ISAKU OKAMOTO, TAKURO OKADA, KUNIHIKO TOKASHIKI, YURI UEDA, HIROKI SATO, TATSUYA ITO and KIYOAKI TSUKAHARA

Anticancer Research September 2024, 44 (9) 4085-4092; DOI: https://doi.org/10.21873/anticanres.17237
Open Access
Maximum Efficacy of Immune Checkpoint Inhibitors Occurs in Esophageal Cancer Patients With a Low Neutrophil-to-Lymphocyte Ratio and Good Performance Status Prior to Treatment
YUYA HIRASAWA, YUTARO KUBOTA, EMIKO MURA, RISAKO SUZUKI, TOSHIAKI TSURUI, NANA IRIGUCHI, TOMOYUKI ISHIGURO, RYOTARO OHKUMA, MASAHIRO SHIMOKAWA, HIROTSUGU ARIIZUMI, ATSUSHI HORIIKE, SATOSHI WADA, TOMOTAKE ARIYOSHI, SATORU GOTO, KOJI OTSUKA, MASAHIKO MURAKAMI, YUJI KIUCHI, KIYOSHI YOSHIMURA, ROBERT M. HOFFMAN and TAKUYA TSUNODA

Anticancer Research August 2024, 44 (8) 3397-3407; DOI: https://doi.org/10.21873/anticanres.17160

Main menu

User menu

Search

Nivolumab

Pages